Zinc Supplementation and the Effects on Pregnancy Outcomes in Gestational Diabetes: a Randomized, Double-blind, Placebo-controlled Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

The study group was 50 women.

By PubMed's age tags, the people studied were adults, women only.

This randomized, double-blind, placebo-controlled clinical trial was conducted among 50 women with GDM.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Newborn's weight, height, head circumference, Apgar score, and hyperbilirubinemia were determined.

What Was Measured

PubMed files the paper under topics including C-Reactive Protein, Diabetes, Gestational, Dietary Supplements, Gluconates, Pregnancy Outcome and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 50 women.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.